Cognitive testing in older primary care patients: A cluster-randomized trial  by Fowler, Nicole R. et al.
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 349-357Diagnostic Assessment & Prognosis
Cognitive testing in older primary care patients:
A cluster-randomized trialNicole R. Fowlera,*,1, Lisa Morrowb, Laurel Chiappettac, Beth Snitzd, Kimberly Huberd,
Eric Rodrigueza, Judith Saxtona,d
aDepartment of Medicine, School of Medicine, Regenstrief Institute, Indiana University, Indianapolis, IN, USA
bDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
cSchool of Education, University of Pittsburgh, Pittsburgh, PA, USA
dDepartment of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USAAbstract Introduction: This study investigated whether neuropsychological testing in primary care (PC) of-N.R.F., B.S., E.R.
related to the article.
grant RC3 AG037357
Software Tools. J.S. r
years 2005 and 2011
2009 from Pfizer Inc.
1Present address: I
versity Center for Agi
mentation, Regenstrie
*Corresponding a
9305.
E-mail address: fo
http://dx.doi.org/10.10
2352-8729/ 2015 T
license (http://creativefices altered physician-initiated interventions related to cognitive impairment (CI) or slowed the rate
of CI progression.
Methods: This 24-month, cluster-randomized study included 11 community-based PC practices ran-
domized to either treatment as usual (5 practices) or cognitive report (CR; 6 practices) arms. From
2005 to 2008, 533 patients aged 65 years and without a diagnosis of CI were recruited; 423
were retested 24 months after baseline.
Results: CR physicians were significantly more likely to order cognitive-related interventions
(P5 .02), document discussions about cognition (P5 .003), and order blood tests to rule out revers-
ible CI (P5 .002). At follow-up, significantly more CR patients had a medication for cognition listed
in their chart (P 5 .02). There was no difference in the rate of cognitive decline between the groups.
Discussion: Providing cognitive information to physicians resulted in higher rates of physician-
initiated interventions for patients with CI.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Age; Alzheimer’s disease; Community-based; Cognitive impairment; Dementia; Mild cognitive impairmentprimary care; Primary care physicians, K.H., and L.C. have no relevant financial interests
J.S. and L.M. have received salary support through
from the National Institute on Aging to Psychology
eceived payment for consultant services between the
from Forest Pharmaceuticals and between 2005 and
ndiana University School of Medicine, Indiana Uni-
ng Research, Center for Health Innovation and Imple-
f Institute, Inc., Indianapolis, IN, USA.
uthor. Tel.: 11-317-274-9021; Fax 11-317-274-
wlern@iupui.edu
16/j.dadm.2015.06.009
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
Age is the single greatest risk factor for the development
of dementia and disorders of cognition. As the proportion of
older adults continues to grow, the coming decade will see a
significant increase in the number of individuals living with
impaired cognition. Trends in health care delivery suggest
that, in the future, many older adults will obtain a majority
of their health care from general practitioners and will not
be referred to dementia specialists. However, identifying
cognitive impairment (CI) in the primary care (PC) setting
remains challenging [1].
Although it has been suggested that best practice care for
older adults should include screening for cognitive disordersimer’s Association. This is an open access article under the CC BY-NC-ND
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States Preventive Services Task Force does not recommend
universal screening in PC, citing performance characteristics
of screening instruments and limited evidence of effective-
ness [3]. Nevertheless, beginning in January 2011, in
compliance with the Patient Protection and Affordable
Care Act, the Centers for Medicare and Medicaid Services
began covering the costs of an annual wellness visit, which
calls for detection of CI by providers conducting the annual
wellness visit [4].
A number of studies have investigated screening for de-
mentia in PC [5–7] but fewer have examined the impact of
screening for mild cognitive impairment (MCI) on older
adults [8–11]. With the current emphasis on earlier
diagnosis of CI, the goal of this study was to determine
whether identifying MCI in older PC patients, without a
dementia diagnosis, would result in a change in physician
practice or slow cognitive decline. Community-based PC
practices were randomized to either treatment as usual
(TAU) or cognitive report (CR) arms. We hypothesized
that PC physicians (PCPs) in the CR group, who received
CRs based on neuropsychological testing, would perform
dementia screening tests, refer patients to specialists for
diagnostic assessment, and prescribe anticholinesterase in-
hibitors more frequently than PCPs in the TAU group. We
also hypothesized that patients of physicians in the CR
group would have a slower rate of progression of cognitive
deficits over 2 years than cognitively impaired patients in
the TAU group (http://clinicaltrials.gov identifier: PCP-
AG023129). We based the hypothesis on the rationale
that patients with reversible CI would have improved
cognition due to its spontaneous resolution or treatment
of the underlying cause. If other causes of impairment
were ruled out and the impairment was thought to be due
to impending Alzheimer’s disease (AD), the decline could
be slowed if the physician prescribed cognitive-enhancing
medications [12].2. Methods
2.1. Design
This study was a 24-month, cluster-randomized trial with
two parallel groups. The unit of randomization was PCP
practice and not individual PCPs nor patients given that
our primary outcome was physician-initiated interventions
and that within practices, physicians frequently are called
on to cover each other’s patients and may exhibit similar
practice patterns [13]. If randomization occurred at the
PCP level, a given PCP could be called on to treat a patient
from the other arm, leading to possible contamination be-
tween groups. Additionally, patients who share PCPs may
share information about cognitive testing and subjective
complaints that could lead to dilution of treatment effects
[14]. Practices were recruited from October 2005 to January
2006; patients were recruited from January 2006 to January2008. The University of Pittsburgh Institutional Review
Board approved the study, and all physician and patient par-
ticipants provided written informed consent.2.2. Setting, participants, and randomization
We stratified 12 PC practices from southwestern Pennsyl-
vania by geographic location (urban, suburban, and rural).
Two of the 12 were classified as urban, and to ensure bal-
ance, they were randomly assigned to intervention or control
with equal probability in a block size of two. Eight of the 12
were classified as suburban, and these sites were stratified by
the number of physicians participating in the study. The
eight suburban sites were also randomly assigned to inter-
vention or control with equal probability in a block size of
four. Two sites were classified as rural were randomly
assigned to intervention or control with equal probability
in a block size of two. Of the 12 practices, six were randomly
assigned to the CR group and received the results of the
patients’ baseline and 24-month assessments. The remaining
six practices were assigned to the TAU group and did not
receive baseline CRs. After randomization, but before
patient recruitment, one suburban practice (with one physi-
cian) dropped out because of perceived study burden,
leaving five TAU practices in the study.
Patients were first approached by physicians who were
instructed to refer all patients aged 65 years without a
dementia diagnosis to the study coordinator. Patients with
a diagnosis of dementia on their medical record, or with
mini-mental state examination (MMSE) [15] scores of 18
or below, which indicates the presence of unrecognized
dementia, were excluded from this study. However, patients
with complaints of memory loss who did not have a diag-
nosis of dementia were not excluded. A total of 731 patients
were referred. Among those, 183 (25%) declined participa-
tion or were ineligible (e.g., ,65 years old, had a notation
of “dementia or Alzheimer’s disease” somewhere within
the medical record, died before enrollment; Fig. 1). Compar-
isons between patients who did and did not participate
demonstrated no significant differences regarding PC
office, physician, geographic location, or group assignment.
A total of 548 patients completed the baseline assessment;
15 (2.7%) were subsequently excluded because they did
not meet study entry criteria (e.g., MMSE ,18, dementia
diagnosis, or the referring physician was not a participating
PCP). The final sample included 533 patients (TAU 5 204,
38.3%; CR 5 329, 61.7%).
Of the initial 533 enrolled participants, 423 (79.4%) re-
turned for the 2-year assessment (TAU 5 169, 82.8%;
CR 5 254, 77.2%). Among the 110 (20.6%) not included
in the 2-year assessment (TAU 5 35, 17.2%; CR 5 75,
22.8%), 18 (16.4%) died (TAU 5 12, CR 5 6), 15
(13.6%) changed PCP (TAU 5 5, CR 5 10), 30 (27.3%)
cited poor health (TAU 5 10, CR 5 20), 27 (24.5%) cited
lack of interest (TAU 5 5, CR 5 22), and 20 (18.1%)
gave no reason (TAU 5 3, CR 5 17).
Fig. 1. Study timeline.
Table 1
Neuropsychological test battery and self-rated questionnaires administered
at baseline and 24 months
Neuropsychological test battery:
Memory: Word list learning test (WLL) [16] with delayed recall,
Wechsler memory scale-revised (WMS-R) logical memory (LM) I and
II [17], and the modified Rey-Osterrieth (mR-O) figure immediate and
delayed recall [18]
Attention/psychomotor speed: WMS-R digit span forward, trail making
test part A [19], and Wechsler adult intelligence scale-revised (WAIS-
R) digit symbol [20]
Visuospatial ability: modified WAIS-R block design and copy of the
mR-O figure
Language abilities: Boston naming test [21] and semantic fluency
(animals) [22]
Executive functions: Trail making test part B, WMS-R digit span
backward, letter fluency (F,A,S), clock drawing, and WAIS-R digit
symbol
Self-rated questionnaires:
Structured interview to assess subjective memory abilities [23]
Activities of daily living (ADLs) and instrumental ADLs [24,25]
Center for Epidemiological Studies-Depression (CES-D) [26,27]
Structured interview documenting self-reported prescription and over-
the-counter (OTC) medications
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The study included multiple measures, including partici-
pant demographics, neuropsychological tests, self-rated
questionnaires, and data extracted from PC medical records
by registered nurses (Table 1. The study nurses extracted
data using a structured chart abstraction tool over four
periods: (1) 12-months before baseline; (2) baseline to
12-months after baseline; (3) 13–24 months; and (4) 25–
30 months. Data extracted from the medical record included
clinical and utilization outcomes, including the medical
problem list, family history of dementia, number of falls,
PCP visits and phone calls, emergency department visits,
hospitalizations, number of medications, number of new
medical problems, and newly initiated advance directives.
For all data collection time points after baseline,
physician-initiated outcomes were recorded from the medi-
cal record. For the purposes of this analysis, the following
outcomes were designated as physician-initiated interven-
tions: discussions about memory or cognitive problems or
dementia; administration of cognitive or functional assess-
ments; referrals to dementia specialists; brain imaging;
blood work to rule out reversible causes; referrals to social
services; prescription and over-the-counter (OTC) medica-
tions; notations of memory or functional impairments from
patient, family, or PCP; contact or discussion with familymember; concern of deviation from medical instructions or
noncompliance with medications; concern of unsafe driving;
presence of advanced directive; and note of any formal or
informal cognitive or functional assessments.
Table 2
Baseline physician and primary care practice characteristics
Practice characteristics (n 5 11) n (%)
Randomization group
Cognitive report 6 (54.5)
Treatment as usual 5 (45.5)
Total number of physicians in practice
(median, min–max)
6.0 (1–26)
Number of study subjects per practice
(median, min–max)
31.0 (8–100)
Geographic location
Urban 2 (18.2)
Suburban 7 (63.6)
Rural 2 (18.2)
Practice size
1–5 physicians in practice 6 (54.5)
.5 physicians in practice 5 (45.5)
Physician characteristics (n 5 24) n (%)
Randomization group
Cognitive report 13 (54.2)
Treatment as usual 11 (45.8)
Age group, y
25–39 2 (4.2)
40–54 7 (25.0)
55 15 (58.3)
Male 20 (83.3)
White 20 (83.3)
Number of patients PCP sees in practice 65-years old
1–200 4 (16.7)
200 15 (62.5)
Unknown 1 (20.8)
Study patients per PCP (mean 6 SD) 17.63 6 13.33 (1–56)
Cognitive report 19.54 6 15.58 (2–56)
Treatment as usual 15.36 6 10.36 (1–36)
Abbreviations: PCP, primary care physicians; SD, standard deviation.
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Participants were first classified as having cognition
within normal, MCI, or dementia ranges using the following
criteria from the University of Pittsburgh Alzheimer Disease
Research Center [28,29]: (1) dementia, scores 2 standard
deviations (SDs) below age norms on two cognitive
domains, one of which must be memory; (2) MCI, at least
two scores 1–2 SDs below age norms; (3) and normal,
individuals not meeting either (1) or (2). The final
diagnosis was determined after adjudication by three
expert neuropsychologists (all licensed psychologists)
based on cognitive scores together with a review of
participants’ demographic, functional, behavioral, and
medical information. Adjudications were conducted blind
to study group status.
2.5. Physician CR
The CR included a graphical display of neuropsycholog-
ical scores, a clinical interpretation of the scores ranges
(normal, MCI, or dementia), a review of medical status
and medications, and recommendations. For individuals
meeting criteria for MCI or dementia, the panel recommen-ded performing a work-up for possible dementia and
provided the PCP with a copy of the American Academy
of Neurology (AAN) guidelines [30]. In cases where the
panel felt that other factors might adversely affect cognition,
additional recommendations were made, including a work-
up for depression and anxiety for patients who endorsed
symptoms on study questionnaires, and a review of medica-
tions prompted by possible anticholinergic side effects or
when patient’s self-reported medication list and the physi-
cian’s chart list did not agree, or when there was a question
of medication compliance or inappropriate use. CR physi-
cians were required to sign, date, and return a receipt stating
they had reviewed the report.2.6. Patient report
CR participants received a letter describing the results
in lay language and instructing them to discuss the re-
sults with their physician. Given the design of the study,
neither patients nor physicians were blind to the treat-
ment arm.2.7. Statistical analysis
Baseline data were examined for outliers and missing
values. Comparisons between study groups were made using
t tests and chi-squared tests, as appropriate, and nonpara-
metric procedures were employed using Mann-Whitney
U or Fisher’s exact tests for analysis.
Cognitive test scores from baseline and 24-month follow-
up were converted to z-scores using baseline scores of
participants with normal cognition as a reference group
(e.g., mean and SD). Average z-scores were calculated for
each of the five cognitive domains and a global z-score
calculated from the mean of the five domains. Finally, the
global z-score at baseline was subtracted from the global
z-score at follow-up for a global z-change score, and a larger
positive value indicates improvement. Z-scores were
analyzed as a continuous variable and a binary variable
(e.g., improvement or decline).
Models were fit with improvement in cognitive status
(z-score) as the dependent variable and randomization
group as the independent. Adjusted models included age
and number of medical problems as covariates. To test
whether improvement in cognitive status was associated
with receiving a CR, we used a generalized estimating
equation [31] model with a random intercept to adjust for
the clustering of patients with physicians and for the clus-
tering of physicians within practices. Statistical signifi-
cance was defined as a P value of ,.05. Analyses were
conducted with IBM SPSS Statistics version 19.0 (SPSS,
Inc., Chicago, IL).
The study was powered so that a sample size of approxi-
mately 120 patients in each group (equivalent to an effective
sample size of 240 patient per group after accounting for
clustering) had a .90% power to determine if there is an
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groups over a 2-year period.3. Results
3.1. Practice and physician characteristics
The PC practices were primarily in suburban locations
(63.6%) and were relatively small (1–5 physicians). The
24 physicians were mostly male (83.3%), aged 55–69 years
(58.3%), and Caucasian (83.3%), and most (62.5%) reported
a panel of more than 200 patients whowere at least 65-years-
old (Table 2).3.2. Patient characteristics
The mean age of study participants at entry was
73.6 years, 50.0% had a high school degree or equivalent
education, 58.9% were female, and 63.8% were married.
The average number of prescription medications at base-
line was 7.89 (SD, 4.16), and 1.7% were taking a prescrip-
tion cognitive-enhancing medication (Table 3). The mean
number of medical problems was 8.13 (SD, 3.81).Table 3
Patient participant baseline characteristics by randomization group
Total (n
Age, y (mean, SD) 73.57 6
Female, n (%) 314 (58
White, n (%) 515 (96
High school or equivalent, n (%) 288 (54
Years of education (mean, SD) 13.83 6
Marital status, n (%)
Married 340 (63
Widowed 130 (24
Other 63 (11
Family history dementia, n (%) 105 (30
Subjective memory less well than 1-y ago, n (%) 177 (33
Instrumental ADL impairment (range 0–30) (mean 6 SD) 0.45 6
CES-D depression score (range 0–21) (mean 6 SD) 2.17 6
Number of prescription medications 7.89 6
Use of at least 1 anti-dementia prescription medication, n (%) 1 (0.2
Use of at least one anti-dementia over-the-counter medication, n (%) 2 (0.4
Number of medical problems (mean, SD) 8.13 6
Hyperlipidemia/cholesterol, n (%) 139 (26
Hypertension, n (%) 368 (69
Arthritis, n (%) 387 (72
Diabetes, n (%) 335 (62
Coronary artery disease, n (%) 60 (11
Myocardial infarct, n (%) 131 (24
Chronic obstructive pulmonary disease, n (%) 50 (9.4
Stroke or TIA, n (%) 62 (11
Cancer, n (%) 128 (24
Baseline cognitive diagnosis, n (%)
Normal status 307 (57
MCI 206 (38
Demented 20 (3.8
Abbreviations: TAU, treatment as usual; CR, cognitive report; SD, standard devia
for Epidemiological Studies-Depression; TIA, transient ischemic attack; MCI, mi
*Comparisons between cognitive report and treatment as usual groups.Arthritis (72.6%) represented the most frequently listed
problem, followed by hypertension (69%), and diabetes
(62.9%).
There were no significant baseline differences between
study groups in the proportion of individuals meeting criteria
for normal (61.5%), MCI (36.9%), and dementia (1.6%;
P 5 .30) either for the total baseline sample of 533
(Table 3) or for the 423 who subsequently returned for the
24-month follow-up testing (P 5 .36).
3.3. Patient outcomes3.3.1. Clinical and utilization outcomes
We found no difference between study groups in any of
the clinical and utilization outcomes (e.g., falls, PCP visits
and phone calls, emergency department visits, hospitaliza-
tions, number of medications, number of new medical prob-
lems, and newly initiated advance directives).
3.3.2. Cognitive outcomes
There was no significant difference between study groups
in change in cognitive status at 24 months (Table 4). The5 533) TAU (n 5 204) CR (n 5 329) Stat, P value*
6.06 73.51 6 5.76 73.60 6 6.25 t 5 0.17, P 5 .87
.9) 107 (52.5) 207 (62.9) c2 5 5.7, P 5 .02
.6) 202 (99.0) 313 (95.1) c2 5 5.8, P 5 .02
.1) 107 (52.5) 181 (55.2) c2 5 0.4, P 5 .54
2.84 13.99 6 2.74 13.73 6 2.90 t 5 1.01, P 5 .31
c2 5 5.2, P 5 .08
.8) 142 (69.6) 198 (60.2)
.4) 40 (19.6) 90 (27.4)
.8) 22 (10.8) 41 (12.5)
.8) 38 (28.8) 67 (32.1) c2 5 0.4, P 5 .52
.2) 65 (31.9) 112 (34.0) c2 5 0.3, P 5 .60
1.26 0.37 6 1.02 0.50 6 1.39 t 5 1.22, P 5 .22
2.88 2.03 6 2.92 2.25 6 2.86 t 5 0.83, P 5 .41
4.16 7.70 6 4.35 8.02 6 4.04 t 5 0.85, P 5 .39
) 0 (0) 1 (0.3) FET, P 5 1.00
) 0 (0) 2 (0.6) FET, P 5 .53
3.81 8.59 6 3.66 7.85 6 3.87 t 5 2.17, P 5 .03
.1) 50 (24.5) 89 (27.1) c2 5 0.4 P 5 .52
.0) 133 (65.2) 235 (71.4) c2 5 2.3, P 5 .13
.6) 151 (74.0) 236 (71.7) c2 5 0.3, P 5 .57
.9) 138 (67.6) 197 (59.9) c2 5 3.3, P 5 .07
.3) 17 (8.3) 43 (13.1) c2 5 2.8, P 5 .09
.6) 39 (19.1) 92 (28.0) c2 5 5.3, P 5 .02
) 16 (7.8) 34 (10.3) c2 5 0.9, P 5 .34
.6) 25 (12.3) 37 (11.2) c2 5 0.1, P 5 .72
.0) 47 (23.0) 81 (24.6) c2 5 0.2, P 5 .70
c2 5 2.4, P 5 .30
.6) 114 (55.9) 193 (58.7)
.6) 85 (41.7) 121 (36.8)
) 5 (2.5) 15 (4.6)
tion; ADL, activities of daily living; FET, Fisher’s exact test; CES-D, Center
ld cognitive impairment.
Table 4
Change in cognitive diagnosis of patient participants from baseline to follow-up by randomization group (n 5 423)
Baseline diagnosis
Randomization group
24-month diagnosis Total Treatment as usual Cognitive report Stat, P value
Normal, n (%) Normal 235 (90.4) 89 (90.8%) 146 (90.1) c2 5 0.03, P 5 1.00
MCI 25 (9.6) 9 (9.2%) 16 (9.9)
Total 260 (100) 98 (100) 162 (100)
MCI, n (%) Normal 70 (44.9) 33 (47.8) 37 (42.5) c2 5 0.44, P 5 .80
MCI 72 (46.2) 30 (43.5) 42 (48.3)
Dementia 14 (9.0) 6 (8.7) 8 (9.2)
Total 156 (100) 69 (100) 87 (100)
Dementia, n (%) MCI 5 (71.4) 1 (50) 4 (80) FET, P 5 1.00
Dementia 2 (28.6) 1 (50) 1 (20)
Total 7 (100) 2 (100) 5 (100)
Abbreviations: MCI, mild cognitive impairment; FET, Fisher’s exact test.
Fig. 2. Repeated measures ANOVA comparing number of physician out-
comes per patient at baseline and follow-up (n 5 163). Group: F 5 0.30,
P 5 .58; time: F 5 14.08, P , .001; group by time: F 5 14.08, P , .001.
Abbreviations: ANOVA, analysis of variance; TAU, treatment as usual;
CR, cognitive report.
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and dementia at follow-up was 72.1%, 24.1%, and 3.8%,
respectively. There was no difference in z-score change be-
tween TAU and CR for each of the diagnostic groups.
Among the 163 cognitively impaired participants
(MCI 5 156; dementia 5 7) from the TAU and CR groups
who returned for the 24-month assessment, there was no sig-
nificant difference in cognitive outcomes between those who
received a physician-initiated intervention (n 5 106) and
those who did not (n 5 57). Additionally, among the 106
who received an intervention, there was no significant differ-
ence in cognitive outcomes between study groups
(TAU 5 39; CR 5 67) (c2 5 0.44, P 5 .80).
3.4. Physician-initiated interventions
All physicians had some patients for whom no interven-
tion was ordered and some with at least one intervention.
Among cognitively impaired patients, the average number
of PCP-initiated interventions per subject increased signif-
icantly between baseline and 24 months in the CR group as
compared with the TAU group (Fig. 2). Overall, CR physi-
cians were more likely than TAU physicians to intervene.
Specifically, CR physicians were significantly more likely
to order blood tests as part of a dementia work-up
(P 5 .002) and document discussions about cognition/de-
mentia with the patient (P 5 .001). Although there was
no difference in prescription rates for cognitive-
enhancing medications, individuals in the CR group were
more likely at follow-up to have either a prescription or
OTC medication for cognition listed on their medical chart
(TAU5 4; CR5 17; P5 .02). Finally, CR physicians were
more likely than TAU physicians to document a discussion
about the study (TAU5 0, 0%; CR5 61, 24.0%; c25 47.4,
P , .001).4. Discussion
The cognitive assessment intervention had no significant
effect on patient cognitive status; however, our findings sug-
gest that when physicians are provided with data and recom-
mendations regarding the cognitive status of older patients,
they use this information to make decisions about treatment
strategies aimed at remediating cognitive decline. Although
there were statistically significant differences between study
groups in the proportion of physician-initiated interventions,
the actual number of medical interventions was surprisingly
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as part of a dementia work-up for 17 of the 92 CR partici-
pants who were reported as having CI. We found such a
low rate surprising given that AAN guidelines recommend
screening for reversible causes of CI and CR physicians
documented that they were aware of the CI in 30 (32.6%)
cases by noting “memory problems” in the medical records
(compared with 21% of TAU cases).
Several studies have suggested that impaired cognition inPC
patients is under-recognized [32,33] and poor recognition has
been attributed to a number of factors, including the difficulty
of identifying subtle cognitive symptoms or changes
overtime, the length of time and perceived complexity of a
dementia evaluation, and the lack of physician confidence in
making cognitive diagnoses [2,3,34,35]. In this study, experts
conducted the cognitive assessments without any time burden
for the PCP or staff; yet, few PCPs took action when a CR
indicated possible MCI or dementia. We considered a number
of reasons that may explain this. We looked first to see if
physicians had conducted their own cognitive assessment
from which they determined that the evidence of CI was not
substantiated. However, our data showed that most physicians
did not conduct, or at least did not document, cognitive
assessments or cognitive screening in the record. Physicians
may have decided to take a “watchful waiting” approach,
perhaps, as a general treatment strategy, but perhaps also
because physicians knew the patients would undergo
retesting, and they may have considered the CR to be an
expert consultation, making additional referral unnecessary.
Additionally, the possibility exists that physicians interpreted
the CR as indicating the presence of early AD and considered
further investigation unnecessary, believing that potentially
treatable causes of CI had been ruled out and that progressive
decline is inevitable. Finally, physicians may have been
reluctant to conduct further work-up regarding cognitive defi-
cits if the patient did not make subjective complaints, suggest-
ing that physiciansmaywish to see evidence ofmore significant
decline. Support for this possibility comes from our finding that
physicians were more likely to intervene when MMSE scores
were lower. Many dementia experts believe that identification
at the very earliest stage of impairment has the greatest impact,
especially in identifying thosewhose cognitive deficits put them
at risk for medication mismanagement that may lead to
increased emergencydepartment andPCPvisits andgreater uti-
lization of services that may be unnecessary, unwanted, or even
harmful.
In addition to the CR, a letter was sent to each patient rec-
ommending that they discuss the results with their physician.
It is not possible from our data to determine howmuch of the
physicians’ treatment response was driven directly by the
CR or by a discussion initiated by the patient. We note that
physicians documented general discussions about cognition
and memory with 43.5% of CR patients as compared with
21.1% of TAU patients.
A follow-up period of 2 years is relatively short given the
long prodromal stage of AD and, thus, it is possible that wemay have seen an effect in the rate of cognitive decline be-
tween the groups with longer follow-up. Although we
controlled for receipt of a CR, we did not control the
PCP’s response to receiving the CR and the clinical determi-
nation of whether to initiate an intervention. We found that
PCPs were more likely to order interventions for older,
more cognitively impaired patients with the greatest number
of medical problems; therefore, it is possible that these indi-
viduals may be less likely to benefit from an intervention
than younger, healthier patients.
Our findings cannot be used to infer prevalence of MCI in
PC settings as this was not an epidemiologic study. More-
over, although the protocol instructed physicians to refer
all patients, they may have referred only patients for
whom they had concerns, thus over-representing MCI in
this sample.
This study has a number of strengths as compared with
previous studies of cognitive assessments in PC patients.
First, to the best of our knowledge, this is the only study to
use a cluster-randomized controlled design in which study
physicians in one group were randomized to receive the re-
sults of a neuropsychological assessment of their patients,
and physicians in the practices randomized to TAU did
not. Second, primary measures were collected over a
24-month period, which allowed us to compare multiple
PCP-patient interactions. Third, the assessment included a
comprehensive cognitive evaluation, rather than a brief
screening measure, resulting in more confidence in the diag-
nosis of MCI and dementia.
At the same time, this study also had limitations. First, an
overwhelming majority of patient participants identified
themselves as white. Second, the method of recruitment
through physician referral could have led to an increase in
the number of patients for whom the physician already had
concerns about cognitive abilities. The small number of
physician practices is also of concern in that there may be
confounding factors not controlled by randomization that
could have influenced our findings. Finally, 25% of individ-
uals referred by their physicians were not eligible or
declined to participate. However, no definitive conclusions
can be made regarding potential bias as data were not
collected for subjects who did not participate.5. Conclusions
In conclusion, we found that physicians who received
CRs were more likely to order diagnostic tests and discuss
memory problems with patients, and patients were more
likely to be taking either a prescription or OTC cognitive-
enhancing medication at follow-up. These findings are rele-
vant to the current controversy regarding cognitive screening
in PC in that we have demonstrated that having available
cognitive information will change physician behavior.
Although the physician response was modest, it is possible
a more significant response will be seen once a more effec-
tive treatment becomes available and once the Medicare
N.R. Fowler et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 349-357356annual wellness visit is more widely adopted, and more
potential cases of CI are detected.
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1. Systematic review: It has been suggested that
optimal care for older adults should include
screening for cognitive disorders to facilitate early
detection and treatment. Yet, the United States Pre-
ventive Services Task Force does not recommend de-
mentia screening in primary care, citing performance
characteristics of screening instruments and limited
evidence of effectiveness.
2. Interpretation: Our study showed that primary care
physicians who receive cognitive data about their pa-
tient initiated interventions that may improve the
quality of care, but there was no impact on overall
rate of patient’s cognitive decline.
3. Future directions: Test the long-term patient and
caregiver outcomes after the cognitive assessments
in primary care.
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